Market Closed -
Nasdaq
04:00:00 2024-05-24 pm EDT
|
5-day change
|
1st Jan Change
|
80.79
USD
|
+0.47%
|
|
-3.60%
|
+4.70%
|
Fiscal Period: June |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
7,896
|
10,094
|
17,511
|
13,600
|
12,852
|
12,731
|
-
|
-
|
Enterprise Value (EV)
1 |
8,235
|
10,179
|
17,621
|
13,609
|
12,997
|
12,909
|
12,714
|
12,478
|
P/E ratio
|
84.4
x
|
45.4
x
|
130
x
|
52.3
x
|
46.4
x
|
72.2
x
|
57.9
x
|
48.7
x
|
Yield
|
0.61%
|
0.48%
|
0.28%
|
0.37%
|
-
|
0.4%
|
0.4%
|
0.41%
|
Capitalization / Revenue
|
11.1
x
|
13.7
x
|
18.8
x
|
12.3
x
|
11.3
x
|
11
x
|
10.2
x
|
9.23
x
|
EV / Revenue
|
11.5
x
|
13.8
x
|
18.9
x
|
12.3
x
|
11.4
x
|
11.1
x
|
10.2
x
|
9.04
x
|
EV / EBITDA
|
31.2
x
|
38
x
|
45.7
x
|
30.3
x
|
29.5
x
|
31.5
x
|
27.7
x
|
24
x
|
EV / FCF
|
52.7
x
|
66.4
x
|
57.2
x
|
48.5
x
|
60.1
x
|
54.6
x
|
39.7
x
|
37.3
x
|
FCF Yield
|
1.9%
|
1.51%
|
1.75%
|
2.06%
|
1.66%
|
1.83%
|
2.52%
|
2.68%
|
Price to Book
|
6.96
x
|
7.53
x
|
11.2
x
|
8.36
x
|
6.72
x
|
6.2
x
|
5.55
x
|
4.92
x
|
Nbr of stocks (in thousands)
|
151,491
|
152,892
|
155,567
|
156,934
|
157,437
|
157,585
|
-
|
-
|
Reference price
2 |
52.12
|
66.02
|
112.6
|
86.66
|
81.63
|
80.79
|
80.79
|
80.79
|
Announcement Date
|
8/6/19
|
8/4/20
|
8/5/21
|
8/4/22
|
8/8/23
|
-
|
-
|
-
|
Fiscal Period: June |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
714
|
738.7
|
931
|
1,106
|
1,137
|
1,159
|
1,248
|
1,380
|
EBITDA
1 |
264.3
|
268.1
|
385.7
|
449.3
|
441
|
409.4
|
459.2
|
519.5
|
EBIT
1 |
244.7
|
246.3
|
362.2
|
421.3
|
410.2
|
371.8
|
421.7
|
480.2
|
Operating Margin
|
34.27%
|
33.34%
|
38.9%
|
38.11%
|
36.09%
|
32.08%
|
33.8%
|
34.81%
|
Earnings before Tax (EBT)
1 |
112
|
276.5
|
148.2
|
301.4
|
338.7
|
206.9
|
273.1
|
344
|
Net income
1 |
96.07
|
229.3
|
140.4
|
272.1
|
285.3
|
179.9
|
224.5
|
266.7
|
Net margin
|
13.46%
|
31.04%
|
15.08%
|
24.61%
|
25.1%
|
15.52%
|
17.99%
|
19.33%
|
EPS
2 |
0.6175
|
1.455
|
0.8675
|
1.658
|
1.760
|
1.118
|
1.396
|
1.660
|
Free Cash Flow
1 |
156.2
|
153.2
|
307.9
|
280.4
|
216.1
|
236.5
|
319.9
|
334.7
|
FCF margin
|
21.88%
|
20.75%
|
33.07%
|
25.36%
|
19.02%
|
20.41%
|
25.64%
|
24.26%
|
FCF Conversion (EBITDA)
|
59.09%
|
57.15%
|
79.82%
|
62.4%
|
49.01%
|
57.76%
|
69.67%
|
64.42%
|
FCF Conversion (Net income)
|
162.59%
|
66.83%
|
219.26%
|
103.06%
|
75.77%
|
131.46%
|
142.47%
|
125.49%
|
Dividend per Share
2 |
0.3200
|
0.3200
|
0.3200
|
0.3200
|
-
|
0.3200
|
0.3200
|
0.3333
|
Announcement Date
|
8/6/19
|
8/4/20
|
8/5/21
|
8/4/22
|
8/8/23
|
-
|
-
|
-
|
Fiscal Period: June |
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
2025 Q3
|
2025 Q4
|
---|
Net sales
1 |
269.3
|
290.4
|
288.2
|
269.7
|
271.6
|
294.1
|
301.3
|
276.9
|
272.6
|
303.4
|
306.3
|
290
|
296.5
|
326.4
|
333
|
EBITDA
1 |
109.5
|
121.8
|
114.3
|
100.5
|
104
|
116.4
|
120
|
95.58
|
93.23
|
109.3
|
112.3
|
102.4
|
106.1
|
123.5
|
127.9
|
EBIT
1 |
102.8
|
114.6
|
106.6
|
93.18
|
96.47
|
108.7
|
111.8
|
86.89
|
81.94
|
99.59
|
103.3
|
93.3
|
96.44
|
112.7
|
117.3
|
Operating Margin
|
38.19%
|
39.45%
|
36.97%
|
34.55%
|
35.52%
|
36.96%
|
37.12%
|
31.38%
|
30.06%
|
32.82%
|
33.72%
|
32.17%
|
32.52%
|
34.52%
|
35.23%
|
Earnings before Tax (EBT)
1 |
86.18
|
68.77
|
79.05
|
103.7
|
66.43
|
80.2
|
88.32
|
49.56
|
33.39
|
61.08
|
63.59
|
55.01
|
60.19
|
78.75
|
81.56
|
Net income
1 |
80.17
|
60.74
|
61.52
|
89.56
|
50
|
70.22
|
75.48
|
50.99
|
27.46
|
49.06
|
52.8
|
41.68
|
47.05
|
61.65
|
64.55
|
Net margin
|
29.77%
|
20.92%
|
21.35%
|
33.21%
|
18.41%
|
23.87%
|
25.05%
|
18.41%
|
10.08%
|
16.17%
|
17.23%
|
14.37%
|
15.87%
|
18.89%
|
19.38%
|
EPS
2 |
0.4850
|
0.3700
|
0.3775
|
0.5525
|
0.3100
|
0.4300
|
0.4700
|
0.3100
|
0.1700
|
0.3100
|
0.3280
|
0.2650
|
0.2950
|
0.3850
|
0.4050
|
Dividend per Share
2 |
0.0800
|
0.0800
|
0.0800
|
0.0800
|
0.0800
|
0.0800
|
-
|
0.0800
|
-
|
-
|
0.0800
|
0.0800
|
0.0800
|
0.0800
|
0.0800
|
Announcement Date
|
2/1/22
|
5/4/22
|
8/4/22
|
11/1/22
|
2/2/23
|
5/3/23
|
8/8/23
|
10/31/23
|
2/1/24
|
5/1/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: June |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
339
|
85.9
|
110
|
8.88
|
146
|
178
|
-
|
-
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
-
|
16.8
|
253
|
Leverage (Debt/EBITDA)
|
1.283
x
|
0.3202
x
|
0.2846
x
|
0.0198
x
|
0.3304
x
|
0.4341
x
|
-
|
-
|
Free Cash Flow
1 |
156
|
153
|
308
|
280
|
216
|
236
|
320
|
335
|
ROE (net income / shareholders' equity)
|
15.6%
|
14.1%
|
9.51%
|
16.6%
|
17.5%
|
14.4%
|
14.7%
|
15%
|
ROA (Net income/ Total Assets)
|
10.1%
|
9.17%
|
6.55%
|
11.9%
|
13%
|
11.6%
|
12.4%
|
13.3%
|
Assets
1 |
952.1
|
2,501
|
2,145
|
2,279
|
2,189
|
1,548
|
1,810
|
2,002
|
Book Value Per Share
2 |
7.490
|
8.760
|
10.00
|
10.40
|
12.10
|
13.00
|
14.60
|
16.40
|
Cash Flow per Share
2 |
1.170
|
1.300
|
2.170
|
1.980
|
1.570
|
1.970
|
2.190
|
2.510
|
Capex
1 |
25.4
|
51.7
|
44.3
|
44.9
|
38.2
|
59.2
|
56.8
|
60.2
|
Capex / Sales
|
3.56%
|
7%
|
4.76%
|
4.06%
|
3.36%
|
5.11%
|
4.55%
|
4.36%
|
Announcement Date
|
8/6/19
|
8/4/20
|
8/5/21
|
8/4/22
|
8/8/23
|
-
|
-
|
-
|
Last Close Price
80.79
USD Average target price
83.77
USD Spread / Average Target +3.68% Consensus |
1st Jan change
|
Capi.
|
---|
| +4.70% | 12.73B | | +67.53% | 63.85B | | -0.77% | 41.83B | | +45.66% | 40.65B | | -10.72% | 27.12B | | +13.30% | 26.52B | | -22.79% | 18.69B | | +24.10% | 12.11B | | +27.41% | 12.07B | | -8.12% | 11.19B |
Other Biotechnology & Medical Research
|